Fluxome finds a last-minute buyer: But is it resveratrol or omega-3 to be sold?
Swiss biotech firm Evolva has agreed to buy undisclosed assets from Fluxome, as it leaves its pure pharma research past in the dust and throws the embattled Danish supplier a lifeline.